Navigation Links
FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures
Date:1/29/2010

breakthrough bleeding, while taking Lamictal XR and birth control pills. These are not all the possible side effects of Lamictal XR.

For full prescribing information for Lamictal XR, including Boxed Warning, please visit www.gsk.com.

Editor's Note: About the Clinical Trial

The approval of Lamictal XR (lamotrigine) as add-on therapy for primary generalized tonic-clonic seizures was based upon data from a 19-week, international, multicenter, double-blind, randomized, placebo-controlled study in 143 patients 13 years of age and older (n = 70 on Lamictal XR and n = 73 on placebo). Patients with at least three primary generalized tonic-clonic seizures during an eightweek baseline phase were randomized to 19 weeks of treatment with Lamictal XR or placebo added to their current antiepileptic drug (AED) regimen of up to two drugs. Patients were dosed on a fixed-dose regimen, with target doses ranging from 200 mg/day to 500 mg/day of Lamictal XR based on concomitant AED(s) (target dose = 200 mg for valproate, 300 mg for AEDs not altering plasma lamotrigine, and 500 mg for enzyme-inducing AEDs).

The primary efficacy endpoint was percent change from baseline in primary generalized tonic-clonic seizure frequency during the double-blind treatment phase. For the intent-to-treat population, the median percent reduction in primary generalized tonic-clonic seizure frequency was 75 percent in patients treated with Lamictal XR and 32 percent in patients treated with placebo, a difference that was statistically significant, defined as a two sided p value < 0.05.

The proportion of patients achieving any particular level of reduction in primary
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Chinese State Food and Drug Administration Approves Company Facility for Producing Solid Dosage Perindopril
2. FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis
3. FDA Approves a High Dose Seasonal Influenza Vaccine Specifically Intended for People Ages 65 and Older
4. FDA Approves Lillys ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
5. FDA Approves Lillys Zyprexa for Two Adolescent Indications
6. US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
7. FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus
8. FDA Approves ZEGERID OTC(TM) for Over-the-Counter Treatment of Frequent Heartburn
9. FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder
10. FDA Approves Agriflu Seasonal Influenza Vaccine
11. FDA Approves Lysteda to Treat Heavy Menstrual Bleeding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Mass. , Aug. 1, 2014  NxStage Medical, Inc. ... dialysis products, today announced that Jeffrey H. Burbank , ... Officer, will present at the 34 th Annual Canaccord ... Boston, MA , on Wednesday, August 13 th ... will be made available at http://ir.nxstage.com/ .  ...
(Date:8/1/2014)... 2014 Arena Pharmaceuticals, Inc. (NASDAQ: ... and reported financial results for the second quarter ... have continued to see encouraging advancements in the ... increase in estimated total prescriptions and estimated total ... Jack Lief, Arena,s President and Chief Executive Officer. ...
(Date:7/31/2014)... 2014 STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye today ... 2014 of $20.0 million, a 10% increase over $18.2 ... a constant currency basis, revenues grew 11% during the ... of 2013.  The effect of foreign currency exchange reduced ...
Breaking Medicine Technology:NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25
... NEW YORK, June 13, 2011 Reportlinker.com ... is available in its catalogue: ... in Key SADC Countries ... aim of this research service is to ...
... 2011 Science, public health, and regulatory highlights from ... this document is designed for credentialed journalists. Release dates and ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... or enforcement actions due to legal limitations. ...
Cached Medicine Technology:Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 2Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 3
(Date:8/1/2014)... Gerontological Society of America (GSA) ... field of aging has chosen Madonna Harrington ... PhD, of the University of Luxembourg; and Philipp ... The London School of Economics and Political Science ... Innovative Publication Awards. , These distinguished honors recognize ...
(Date:8/1/2014)... 2014 Lifeinsurancenomedicalexam.info has released a ... for clients who have high cholesterol levels. , ... and qualify for no medical exam life insurance. These ... background medical check-ups. , Since there are no medical ... will qualify in just a few minutes. However, this ...
(Date:8/1/2014)... August 01, 2014 Home Care Assistance ... seniors, is honored to be recognized as a 2014 Best ... given to home care providers who rank in the top ... on monthly satisfaction interviews conducted by Home Care Pulse. , ... home care businesses, the best of the best!” says Home ...
(Date:8/1/2014)... aesthetic injectable procedures have grown in popularity as more ... As Botulinum toxin generally known as BOTOX ... health professionals have emerged to perform procedures utilizing this ... Spinelli, MD from the Division of Plastic Surgery Presbyterian ... from Columbia University in New York have assessed the ...
(Date:8/1/2014)... CapsCanada, a leading provider of ... new K-CAPS® (HPMC capsules) manufacturing facility in Lakeshore, ... last year while experiencing growing global demand for ... “KCAPS® are currently sold in more than 60 ... to other HPMC capsules, K-CAPS® have exceptional appearance ...
Breaking Medicine News(10 mins):Health News:Harrington Meyer, Leist, Hessel, Avendano to receive GSA's 2014 Kalish awards 2Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2Health News:Cincinnati Senior Care Company Receives 2014 Best of Home Care® Employer of Choice Award 2Health News:Plastic surgeons or nurses: Who are the better injectors? 2
... focused on the use of cholesterol-lowering drugs also ... and C-reactive protein levels. C-reactive protein is a ... inflammation in the arteries. One study shows C-reactive ... cardiovascular risk.,Researchers focused on whether the lower low-density ...
... heart's own can, such as raising the heart rate when ... hill but researchers say a pacemaker created by // stem ... shown that genetically engineered heart cells from human embryonic stem ... to a new study. Researchers injected clusters of human beating ...
... body’s immune system and help protect the body against ... shows promising treatment for acute myelogenous leukemia // ... from a patient’s family member. Researchers say this ... cancer of the bone marrow that has become resistant ...
... unexpected structural differences in the brains of cocaine addicts. ... brain structure // of 27 cocaine addicts to that ... ,Results showed the amygdala -- a key structure in ... brain's reward processing system -- is smaller in cocaine ...
... more important factor associated with childhood allergies and asthma than ... to a new study . // ,The study ... a sample of their cord blood serum taken at birth ... showing a sensitization to certain allergens.The children were assessed at ...
... Epilepsy is a disorder caused by abnormal surges in the ... is found to affect more than 2 million people worldwide. ... by just taking medications. // ,Researchers now say that ... effective surgery is compared to drug therapy when treating those ...
Cached Medicine News:
The AIA-600 II has become the new standard in benchtop immunoassay analyzers....
... The ACON PSA Semi-Quantitative Prostate Specific ... Blood/Serum/Plasma) are lateral flow tests in strip ... of Prostate Specific Antigen (PSA). The tests ... ng/mL cut-off values, and all come with ...
... Assess Functional Vision, Quality of Vision ... controls both target illumination and glare ... testing results. Day/Night testing with/without glare ... Standards and all ANSI standards. All ...
... is Recognized as a Valuable Tool ... by Early Eye Disease. Near Test ... 7 in (12.7cm x 17.78cm) Can ... Refractor,Distance Test F.A.C.T. 201: Size ...
Medicine Products: